This phase I trial investigates the side effects and best dose of CD19 positive (+) specific
CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute
lymphoblastic leukemia, non-Hodgkin lymphoma, small lymphocytic lymphoma, or chronic
lymphocytic lymphoma. Sometimes researchers change the genetic material in the cells of a
patient's T cells using a process called gene transfer. Researchers then inject the changed
T-cells into the patient's body. Receiving the T-cell infusion may help to control the
disease.